FDA approves Breyanzi as the first CAR T-cell therapy for marginal zone lymphoma

Later-Stage HumanFDA-approved for the exact stated cancer/useNot addressed

The FDA approved lisocabtagene maraleucel (Breyanzi), a CD19-directed CAR T-cell therapy that genetically engineers a patient’s own T-cells to target and kill cancer cells, for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy — the first and only FDA-approved CAR T-cell therapy for this cancer type, and Breyanzi’s fifth approved cancer type overall, the most of any CD19-directed CAR T-cell therapy. The approval was based on the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial (ClinicalTrials.gov NCT04245839), which enrolled adults with R/R MZL who had received at least 2 lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or who relapsed after stem cell transplantation; the intent-to-treat overall response rate was 84.4% with a 55.8% complete response rate.

What This Means

In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and a complete response rate of 55.8% in adults with relapsed/refractory marginal zone lymphoma, supporting the first FDA approval of any CAR T-cell therapy for this cancer type.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group -- this record makes no claim that CAR T-cell therapy outperforms other MZL treatment options head-to-head, which would require a randomized trial. CAR T-cell therapies carry known risks including cytokine release syndrome and neurologic toxicity, requiring specialized administration and monitoring.

Why It Matters

Marginal zone lymphoma is a genuinely rare, indolent lymphoma subtype with historically limited options once standard therapies fail -- a real, novel cellular-therapy option for this specific population represents meaningful progress, and adds real depth to this site's lymphoma coverage with a different mechanism (cell therapy) than its existing records.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: Later-Stage Human.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 2 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with relapsed or refractory marginal zone lymphoma (MZL) who had received at least 2 lines of prior systemic therapy (including an anti-CD20 antibody and an alkylating agent) or who relapsed after stem cell transplantation, enrolled in the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. (Adults)

Requires specialized apheresis, manufacturing, and administration at a certified treatment center, with intensive post-infusion monitoring -- not a broadly accessible outpatient treatment. This record has not independently reviewed the full safety/tolerability data, which should be added before publication.

Full evidence details

Study design: Non-randomized trial

Funding & Conflicts

Sponsor/developer: Bristol Myers Squibb -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with relapsed or refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.
Biomarker requirement: CD19-expressing B-cell lymphoma (target of the CAR T-cell construct; not a patient-selection biomarker test)
Decision date: 2025-12-04
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

TRANSCEND FL trial registry (marginal zone lymphoma cohort) (opens in a new tab) (Clinical-trial registry) NCT04245839 Load-bearing source NCT04245839
TRANSCEND FL trial registry (marginal zone lymphoma cohort). NCT04245839.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13